Bye-bye, Actavis. The drugmaker has officially adopted its recent buyout's moniker, meaning it'll be known as Allergan from here on out.
Western drugmakers have long struggled with India's populist attitude toward patents, but hoped there would be some light at the end of the tunnel with the latest spate of trade negotiations over generic drugs in the country. But Doctors Without Borders is none too pleased with the proposed trade changes and is urging Prime Minister Narendra Modi to adopt a similar attitude and stand up to international pressure.
Biotech is booming, there's no escaping that fact. And once again, an employment report shows that the biotech boom extends to job growth that beats pharma. Once again, biotech payrolls are burgeoning as pharma's falter.
PatientsLikeMe has been on a roll as of late, inking deals with biopharma giants such as AstraZeneca, Genentech and Biogen to provide its patient-reported data for the companies' R&D initiatives. Now the company is shifting gears, planning to work with the FDA to see how its patient reports could improve drug safety.
The FDA has already admitted that it made a mistake with its initial approval letter for Vanda Pharmaceuticals' sleep disorder drug early last year, a consumer advocacy group says. And now, that group is demanding the agency do a better job fixing it.
Some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it.
Earlier this year, Novartis became the owner of a number of new oncology assets thanks to its multibillion-dollar asset swap with GlaxoSmithKline. And Friday, it released some positive new survival data for leukemia drug Arzerra that adds to the evidence that the trade was a good one for the Swiss drugmaker.
When the FDA approved Wyeth's antidepressant Pristiq in 2008, the nod came with a number of provisions to do postmarketing studies, including one in pediatric patients. Seven years later, Pfizer, which bought Wyeth in a 2009 megamerger, has fulfilled that obligation to disappointing results. The drug failed to hit its endpoint.
New hep C meds have drawn their fair share of criticism, with lawmakers, patients and payers claiming that the drugs' hefty price tags unfairly restrict their use to the sickest patients. Now, more voices are joining the swelling chorus of discontent as two inmates are suing the Massachusetts state prison system for not providing the drugs to prisoners.
Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during pregnancy, the pharma giant has again convinced a jury that there was no credible connection. The results are positive for Pfizer, but the company still faces more than 1,000 lawsuits alleging similar claims.
Earlier this week, Chinese authorities released Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--from local prison after a court reduced his sentence by about 7 months. And now, The Wall Street Journal reports that they've released his wife and partner Yu Yingzeng, too, cutting short her sentence by one month.
Proton pump inhibitors, including AstraZeneca's longtime blockbuster Nexium, are some of the most commonly used drugs in the world to treat heartburn. But they may also be increasing the risk of heart attack, a new study shows.
Gilead Sciences and AbbVie are quick to tout the efficacy of their hep C meds. Now, those numbers have helped the drugmakers score a win in the U.K. as the country's National Health Service (NHS) will spend £190 million ($294 million) for new treatments for the disease, including AbbVie's interferon-free treatment and Gilead's blockbuster hep C therapies.
No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?
In their last letter to Mylan Chairman Robert Coury, Teva's leaders made it explicitly clear: They're proceeding down their takeover path whether Mylan likes it or not. And they took another step forward this week, further hiking Teva's stake in their target.
In game theory, the so-called Judo strategy involves using the size and strength of opponents against them. And that's exactly what Yale Professor Barry Nalebuff thinks Merck should employ when it rolls out its next-gen hepatitis C regimen, setting up a battle with Gilead and AbbVie.
The Obama administration is backing off of drug-price protections in the big Trans-Pacific Partnership treaty now under negotiation, The New York Times reports. But U.S. negotiators are still pressing for more power to get involved in government decisions on reimbursement rates.
Industry watchers are keeping a close eye on Bayer's big divestment plans, which involve jettisoning its plastics unit before mid-2016. But meanwhile, it's getting a jump on the slim-down process with the sale of its diabetes care business.
Novartis has the first next-gen psoriasis med on the market in Cosentyx, and it's been spending money to take that first-to-market advantage as far as it can. But the Swiss drugmaker wants the treatment to be first in other indications, too. On that front, it got a boost on Wednesday with some new results in ankylosing spondylitis.
A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira, and by default Pfizer. It found that patients who were switched to the copy did just as well, with no unexpected side effects, as they had on Merck and Johnson & Johnson's Remicade.